TISIDB

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted, extracellular space, extracellular matrix
Domain	PF05986 ADAM-TS Spacer 1 PF01562 Reprolysin family propeptide PF01421 Reprolysin (M12B) family zinc metalloprotease PF00090 Thrombospondin type 1 domain
Function	Metalloprotease that may play a role in the degradation of COMP. Cleaves also alpha-2 macroglobulin and aggregan. Has anti-tumorigenic properties.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0002062 chondrocyte differentiation GO:0003158 endothelium development GO:0003159 morphogenesis of an endothelium GO:0006029 proteoglycan metabolic process GO:0006516 glycoprotein catabolic process GO:0007160 cell-matrix adhesion GO:0009100 glycoprotein metabolic process GO:0030167 proteoglycan catabolic process GO:0031589 cell-substrate adhesion GO:0032330 regulation of chondrocyte differentiation GO:0032331 negative regulation of chondrocyte differentiation GO:0034612 response to tumor necrosis factor GO:0035239 tube morphogenesis GO:0035728 response to hepatocyte growth factor GO:0035729 cellular response to hepatocyte growth factor stimulus GO:0035924 cellular response to vascular endothelial growth factor stimulus GO:0048012 hepatocyte growth factor receptor signaling pathway GO:0050727 regulation of inflammatory response GO:0051216 cartilage development GO:0060562 epithelial tube morphogenesis GO:0061035 regulation of cartilage development GO:0061037 negative regulation of cartilage development GO:0061154 endothelial tube morphogenesis GO:0061448 connective tissue development GO:0070555 response to interleukin-1 GO:0071347 cellular response to interleukin-1 GO:0071356 cellular response to tumor necrosis factor GO:0071772 response to BMP GO:0071773 cellular response to BMP stimulus GO:0090287 regulation of cellular response to growth factor stimulus GO:0090288 negative regulation of cellular response to growth factor stimulus GO:1901136 carbohydrate derivative catabolic process GO:1901509 regulation of endothelial tube morphogenesis GO:1902202 regulation of hepatocyte growth factor receptor signaling pathway GO:1902203 negative regulation of hepatocyte growth factor receptor signaling pathway GO:1902547 regulation of cellular response to vascular endothelial growth factor stimulus GO:1902548 negative regulation of cellular response to vascular endothelial growth factor stimulus GO:1905330 regulation of morphogenesis of an epithelium GO:2001112 regulation of cellular response to hepatocyte growth factor stimulus GO:2001113 negative regulation of cellular response to hepatocyte growth factor stimulus
Molecular Function	GO:0004175 endopeptidase activity GO:0004222 metalloendopeptidase activity GO:0008237 metallopeptidase activity
Cellular Component	GO:0005578 proteinaceous extracellular matrix

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5083635: Defective B3GALTL causes Peters-plus syndrome (PpS) R-HSA-1643685: Disease R-HSA-3906995: Diseases associated with O-glycosylation of proteins R-HSA-3781865: Diseases of glycosylation R-HSA-392499: Metabolism of proteins R-HSA-5173214: O-glycosylation of TSR domain-containing proteins R-HSA-5173105: O-linked glycosylation R-HSA-597592: Post-translational protein modification

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ADAMTS12 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ADAMTS12 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ADAMTS12 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.033	0.00245
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.227	0.0489
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.886	0.0816
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.925	0.0135
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.132	0.552
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.658	0.793
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.207	0.711
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.255	0.782
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.065	0.951
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.412	0.665
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.964	0.0809
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.248	0.274

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ADAMTS12 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	33.3	-23.3	0.423
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	6.8	8	0.247
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	8.5	6.3	0.453
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	16.7	-4.2	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	0	7.9	0.26
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADAMTS12. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADAMTS12. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADAMTS12. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADAMTS12. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ADAMTS12 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ADAMTS12 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ADAMTS12
Name	ADAM metallopeptidase with thrombospondin type 1 motif, 12
Aliases	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12; PRO4389; ADAM ......
Chromosomal Location	5q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ADAMTS12 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ADAMTS12